Skip to content

Welcome to Discover Pharma! Today is : November 8, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

rare disease therapeutics

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Polaryx advances Phase 2 trial of PLX-200 in four rare diseases

    Polaryx Therapeutics is preparing to start its Phase 2 SOTERIA [...]

    August 26, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Evogene and Tel Aviv University join forces to tackle metabolite aggregation in metabolic diseases

    Evogene Ltd. has announced a scientific collaboration with Professor Ehud [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Formation Bio launches $600M drug development fund
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Research & Development
  • ETH Zurich develops electronic implant to lower blood glucose
    Categories: Digital & Data, Drug Discovery & Development, Medical devices, Research & Development, Therapeutic Areas
  • Mineralys reports lorundrostat results in hypertension and kidney disease
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top